On January 15, 2026 Oxford Vacmedix (OVM), the UK-based biotech company developing novel immunotherapies to treat cancer reported the publication of the Phase 1a results in eClinical Medicine, a journal of the Lancet group. The Phase 1 clinical trial of OVM-200, which is now nearing completion, is a multicentre, open‑label, first‑in‑human evaluation of OVM‑200, an immunotherapy developed using Oxford Vacmedix’s Recombinant Overlapping Peptide (ROP) therapeutic platform. Patients with advanced non‑small cell lung cancer, ovarian cancer, or prostate cancer are being treated in the trial. In Phase 1a 12 patients received three subcutaneous doses (250, 500, 1,000, or 2,000μg) of OVM‑200 at 2‑week intervals.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The results demonstrate very good progress toward the primary and secondary endpoints for the trial;

Excellent Safety Profile (primary endpoint): OVM‑200 is very well tolerated at all dose levels. There have been no serious adverse drug reactions and no dose‑limiting toxicities. The only adverse effects were Grade 1 injection‑site reactions.
Very strong Immunogenicity (secondary endpoint): the immune response for both antibodies and T cells has been measured. Both measurements showed a very strong immune response with the antibody response being sustained over 6 months. The 2,000μg cohort generated the strongest immune response.
Therapeutic Dose established for Phase 1b: based on the immune response seen the 2,000μg dose was chosen for the Phase 1b continuation of the trial. Patients could receive up to 11 doses of 2,000μg in Phase 1b.
Professor Shisong Jiang, founder and Chief Scientific Officer of Oxford Vacmedix, said:

We are very pleased to have this publication of the first clinical results for immunotherapies developed using our ROP technology – our first step toward providing accessible immunotherapy for all patient types. This progress has only been possible through the hard work of many people in the labs and in the clinic.

William Finch, Chief Executive Officer of Oxford Vacmedix, said:

This publication marks an important milestone for the company and shows the potential of the ROP technology. We are very pleased with the results and with the trial now nearing completion are already in discussion with potential Series B investors to fund Phase 2 trials for OVM-200.

(Press release, Oxford Vacmedix, JAN 15, 2026, View Source;utm_medium=rss&utm_campaign=publication-of-ovm-200-phase-1a-results [SID1234662057])